Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

drug protocol number
C3731003
drug sponsor
Pfizer
drug study
PF-07055480 (formerly SB-525)
drug trial site
King Faisal Specialist Hospital and Research Center (Riyadh)
drug status
Ongoing
drug phase